Novacyt S.A. (NCYT.L) LSE
54.00
-14(-20.59%)
Currency In GBp
- General
- Statistics
- Historical Data
- Profile
- Financials
54.00
-14(-20.59%)
Currency In GBp
Address
13 Avenue Morane Saulnier
Le Vésinet, 78140
France
Phone
33 1 39 46 51 04
Website
Sector
Healthcare
Industry
Medical - Devices
Employees
234
First IPO Date
November 01, 2017
| Name | Title | Pay | Year Born |
| Lyn Dafydd Rees | Chief Executive Officer & Executive Director | 355,111 | 1973 |
| Steve Gibson | Chief Financial Officer, Company Secretary & Director | 416,049 | N/A |
| Joanne Mason | Chief Scientific Officer & Director | 506,682 | 1975 |
| Peter Coyne | Chief Operations Officer | 0 | N/A |
| Wendy Cox | Director of HR | 0 | N/A |
| Paul Oladimeji | Group Head of R&D | 0 | N/A |
Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. It serves hospitals and corporates. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.